Published in J Cardiovasc Transl Res on May 01, 2010
Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol (2014) 0.86
Circulating microRNA expression profile and systemic right ventricular function in adults after atrial switch operation for complete transposition of the great arteries. BMC Cardiovasc Disord (2013) 0.85
miRNA-548c: a specific signature in circulating PBMCs from dilated cardiomyopathy patients. J Mol Cell Cardiol (2013) 0.82
A MicroRNA-Transcription Factor Blueprint for Early Atrial Arrhythmogenic Remodeling. Biomed Res Int (2015) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res (2007) 17.46
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet (2004) 12.97
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell (2007) 12.72
A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60
Control of stress-dependent cardiac growth and gene expression by a microRNA. Science (2007) 12.08
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
Intronic microRNA precursors that bypass Drosha processing. Nature (2007) 9.65
The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell (2007) 7.70
Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol (2003) 6.99
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev (2008) 5.39
MEF2: a central regulator of diverse developmental programs. Development (2007) 4.70
Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett (2005) 4.63
Stress pathways and heart failure. Cell (1999) 3.80
Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A (2007) 3.72
beta-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 3.43
Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality. PLoS Comput Biol (2008) 3.41
Controversies in ventricular remodelling. Lancet (2006) 3.39
MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res (2008) 3.30
Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res (2008) 3.18
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell (2008) 3.10
Common logic of transcription factor and microRNA action. Trends Biochem Sci (2004) 2.95
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest (2005) 2.65
MicroRNAs and cardiac pathology. Nat Rev Cardiol (2009) 2.50
miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol (2008) 2.42
MicroRNA regulation of cardiovascular development. Circ Res (2009) 2.42
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 2.33
Phenotyping hypertrophy: eschew obfuscation. Circ Res (2003) 2.32
The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res (2006) 2.29
MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol (2009) 2.18
Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet (2002) 1.93
Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Reverse engineering gene networks to identify key drivers of complex disease phenotypes. J Lipid Res (2006) 1.69
Retracted Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem (2009) 1.33
Pathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell line. Funct Integr Genomics (2006) 1.23
Insights into the organization of biochemical regulatory networks using graph theory analyses. J Biol Chem (2008) 1.22
Searching for miR-acles in cardiac fibrosis. Circ Res (2009) 1.19
Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail (2009) 1.17
A study of microRNAs in silico and in vivo: bioinformatics approaches to microRNA discovery and target identification. FEBS J (2009) 1.07
Role of microRNAs in cardiac hypertrophy and heart failure. IUBMB Life (2009) 1.05
Intracellular devastation in heart failure. Heart Fail Rev (2008) 1.04
Put your chips on transcriptomics. Circulation (2008) 0.93
Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int J Biochem Cell Biol (2008) 0.81
New therapeutics for chronic heart failure. Annu Rev Med (2002) 0.78
A systems-based framework for understanding complex metabolic and cardiovascular disorders. J Lipid Res (2008) 0.77
Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A (2003) 3.99
Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev (2005) 1.73
Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res (2012) 1.51
Interaction of G-protein βγ complex with chromatin modulates GPCR-dependent gene regulation. PLoS One (2013) 1.43
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem (2006) 1.38
Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res (2003) 1.15
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol (2007) 1.12
Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol Sci (2011) 1.12
Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem (2010) 1.10
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst (2010) 1.08
"Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem (2004) 1.08
Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem (2005) 1.07
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. Hypertens Res (2010) 1.03
Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res (2010) 1.00
Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res (2004) 0.98
TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J Biol Chem (2002) 0.97
Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2. J Biol Chem (2002) 0.95
G-protein-dependent cell surface dynamics of the human serotonin1A receptor tagged to yellow fluorescent protein. Biochemistry (2004) 0.89
Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. J Biol Chem (2012) 0.89
Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proc Natl Acad Sci U S A (2006) 0.89
Unconventional homologous internalization of the angiotensin II type-1 receptor induced by G-protein-independent signals. Hypertension (2005) 0.89
Manifold active-state conformations in GPCRs: agonist-activated constitutively active mutant AT1 receptor preferentially couples to Gq compared to the wild-type AT1 receptor. FEBS Lett (2007) 0.88
Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun (2009) 0.83
Mechanism of GPCR-directed autoantibodies in diseases. Adv Exp Med Biol (2012) 0.82
Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor. PLoS One (2012) 0.82
Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. PLoS One (2013) 0.80
Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan. Clin Exp Hypertens (2010) 0.80
Site-specific cleavage of G protein-coupled receptor-engaged beta-arrestin. Influence of the AT1 receptor conformation on scissile site selection. J Biol Chem (2008) 0.79
Angiotensin II receptor-induced cardiac remodeling in mice without angiotensin II. Hypertension (2012) 0.78
Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3. Biochim Biophys Acta (2012) 0.78
Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J (2004) 0.77
A protein tyrosine phosphatase inhibitor, pervanadate, inhibits angiotensin II-Induced beta-arrestin cleavage. Mol Cells (2009) 0.76
AT1 receptor induced alterations in histone H2A reveal novel insights into GPCR control of chromatin remodeling. PLoS One (2010) 0.75
Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation. PLoS One (2016) 0.75
Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst (2011) 0.75
Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type1 Receptor. J Chem Inf Model (2017) 0.75